Mylan N.V. (NASDAQ:MYL) will collaborate with non-profit drug developer TB Alliance to advance a new drug called pretomanid in two combination regimens to treat tuberculosis (TB). The two regimens ...
The U.S. generics world has changed. Starting from around late 2018 to early 2019, traditional generics bigwigs Teva, Mylan, Novartis' Sandoz, Amneal and Endo have lost out to a group of six ...
NEW YORK, HERTFORDSHIRE, England and PITTSBURGH - April 18, 2019 - Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration ...
CANONSBURG (dpa-AFX) - Mylan N.V. (MYL), and TB Alliance, a not-for-profit drug maker struck a deal to make the experimental drug pretomanid available for use in two investigational drug regimens to ...
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share ...
The major manufacturers covered in this report GSK Teikoku Seiyaku Johnson & Johnson Novartis AG Mylan N.V. Bayer Lingrui Sanofi Teva Pharmaceutical Industries Luye Pharma Group Hisamitsu ...
Edison, NJ -- (SBWIRE) -- 04/17/2019 -- A new business intelligence report released by HTF MI with title "Global Barbiturate Drugs Market Research Report 2019" has abilities to raise as the most ...
Complete Study of Small Molecule API Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the Small Molecule ...
Daniel Gallagher, then a nominee for the U.S. Securities and Exchange Commission, speaks before the Senate Banking Committee in Washington, D.C., U.S., on June 14, 2011. Photo: Andrew Harrer/Bloomberg ...
Daniel Gallagher, who is stepping down as chief legal officer of Mylan NV next week, plans to join WilmerHale as deputy chair of the law firm’s securities practice. The move will be a homecoming for ...